Review of ibuprofen medicines has begun

The European Medicines Agency's  Pharmacovigilance Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks.

The European Medicines Agency's  Pharmacovigilance Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks with systemic ibuprofen taken over long periods. 
The review was triggered at the request of the UK’s regulatory authority MHRA.
The concerns is that high doses of ibuprofen could have a similar cardiovascular risk to those of COX-2 inhibitors.
Nevertheless ibuprofen is usually taken at lower doses and just for short periods of time.
The usual dose for people over 12 years of age is 200 to 400 mg, 3-4 times a day as needed.
The cardiovascular risks are going to be evaluated in high-doses of ibuprofen - 2,400 mg per day.
 

Original source

Registration

Register for receiving PharmaAround news, register for PharmAround events.
Continue registration